Takeda Pharmaceutical has acquired all outstanding ordinary shares and warrants of TiGenix.
Originally announced in January, the acquisition of the biopharmaceutical company that develops stem cell therapies was valuated at approximately $604 million. According to Takeda, the acquisition will further new treatments for patients with gastrointestinal disorders.
The TiGenix’s board unanimously supported Takeda’s acquisition agreement.
Read the full release